MASYAP joins stakeholder consultation for the AMP HIV prevention study
MASYAP represented Malawi at a consultation in Cape Town on the AMP study, which is testing whether the VRC01 antibody can prevent HIV.
The HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) are working together on the AMP study, which is testing whether a laboratory-made anti-HIV antibody called VRC01 can prevent HIV infection in people at high risk.
- About 1,500women taking part across sub-Saharan Africa
- 2Malawi sites: Queen Elizabeth and Kamuzu Central Hospitals
The consultation
MASYAP was one of a small number of organisations representing Malawi at the study’s two-day stakeholder consultation in Cape Town, South Africa, on 11–12 August 2016. The meeting aimed to build dialogue, mutual understanding and partnership around the study.
Organisations presented the programmes they run in their communities, and MASYAP’s work was found to be well aligned with the goals and strategies of HPTN and HVTN.
What happens next
MASYAP will raise awareness of the trial among its 1,500 members in Blantyre and the surrounding districts, and some members may volunteer to take part.
